CleanCap® M6 – the newest cap analog in the portfolio
From the first CleanCap analog launched in 2017, TriLink has been continuing to improve on its revolutionary capping technology. With the introduction of the CleanCap M6 technology, we have combined the modification of 3’OMe on the m7-Guanosine and the additional methyl modification on the +1 Adenosine, to help improve mRNA potency with the highest protein expression of any CleanCap analog yet.
In internal comparison studies, our newest cap analog- CleanCap M6 - promoted higher protein translation (FLuc) than observed with other CleanCap analogs, driving an increase in the potency of your mRNA drug substance.
When compared to enzymatic capping strategies, the CleanCap M6 analog demonstrated significantly higher protein translation (FLuc), resulting in higher manufacturing yields.
Shortens therapeutic mRNA manufacturing process time per batch by nearly a week compared to enzymatic capping.
Has demonstrated a reduction in overall manufacturing costs 20-40% lower than other capping methods.
Allows you to accelerate product development deadlines and cost-saving targets.